Cereno Scientific broadens its pipeline - signs agreement on acquisition of compound in preclinical phase
Cereno Scientific announced today that the company has signed an agreement with Inorbit Therapeutics AB regarding the acquisition of a new compound in preclinical phase. The compound CS036 provides a further extension of Cereno Scientific's portfolio in cardiovascular diseases.– As an obvious next step of our broadening of the company's priority indication areas, I am very pleased that we have expanded our portfolio of drug candidates with another new compound, CS036, says Cereno Scientific's CEO Sten R. Sörensen. Earlier this year, Cereno Scientific communicated an acquisition of the